secwatch.observer — SEC 8-K summary
======================================

Issuer:     GLOBUS MEDICAL INC (GMED)
CIK:        0001237831
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001562762-24-000124
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Globus Medical Q1 net sales $606.7M (+119% YoY); raises FY2024 guidance
-----------------------------------------------------------------------

- Net sales $606.7M, up 119.3% YoY, driven by NuVasive addition and higher spine/enabling tech volumes.
- GAAP net loss $7.1M (($0.05) diluted EPS); non-GAAP diluted EPS $0.72, up 36.4% from $0.53.
- Non-GAAP adjusted EBITDA $166.6M, or 27.5% of net sales.
- FY2024 revenue guidance raised to $2.460-2.485B; non-GAAP EPS guidance raised to $2.75-2.85.
- Integration of NuVasive progressing; management cites strong surgeon and sales force retention.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/0001562762-24-000124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1237831/000156276224000124/gmed-20240507x8k.htm
  HTML page:      https://secwatch.observer/filing/0001562762-24-000124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer